AllazoHealth Names Dr. Linda Schultz as Chief Customer Success Officer


New York, NY – AllazoHealth, the healthcare technology company using artificial intelligence (AI) to improve medication behaviors through personalized patient experiences, announced today that Linda Schultz, PharmD has been named Chief Customer and Clinical Officer. Dr. Schultz has been with the company since 2019 and has been leading the clinical, operational, reporting, and account management functions. Her leadership and operational excellence fuels the company’s efforts to deliver value at all phases of a client relationship, including some of the world’s largest pharmaceutical companies

“AllazoHealth is widely recognized as a leading AI and machine learning solution in the healthcare industry as it predicts, prioritizes, and personalizes optimal interventions to ensure more successful patient outcomes,” said Dr. Schultz. “I am eager to accelerate innovation in the healthcare industry, and AllazoHealth is a perfect fit.”

Dr. Schultz brings more than 25 years of experience in the managed care segment to her role. Prior to joining AllazoHealth, Dr. Schultz was the owner of a successful boutique consulting firm, RxHorizons, where she provided expertise to address a broad array of strategic pharmacy management and clinical initiatives in various organizations. That experience, coupled with prior roles such as Staff VP of Clinical Pharmacy at Anthem, makes her uniquely qualified to lead the Customer Success and Clinical functions at AllazoHealth.

“AllazoHealth has realized a significant increase in growth. As demand continues to rise for AllazoHealth’s AI solution, we remain focused on delivering value to clients early and often,” said Chief Executive Officer William Grambley. “With Linda’s extensive experience in strategic management and customer success in the managed care space, we can strengthen our commitment to our customers and target market.”

“I am thrilled to lead the AllazoHealth team as we accelerate growth, build out the team, and bring new AI innovations to the pharmaceutical industry,” Dr. Schultz said.